Contribute Try STAT+ Today

WASHINGTON — President Biden will soon have to nominate someone to helm the Food and Drug Administration. His two top contenders couldn’t have more divergent visions for how to lead that agency.

His decision comes at a crucial moment for an agency that has been, at least at times, overlooked by past presidents: The FDA is still in the throes of the Covid-19 pandemic, and regulators are working around the clock to review the new application for what is likely to be the third Covid-19 vaccine authorized for use in the United States. Meanwhile, the agency is facing renewed criticism of its speed, and there are early signs that the FDA is beginning to review some of the questionable scientific decisions made under the tutelage of former Commissioner Stephen Hahn.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Dr. Woodcock disqualified herself with her horrible meddling, overruling the entire review hierarchy (including the AdComm), to single-handedly bow to public pressure and approve Exondys 51 (eteplirsen)

Comments are closed.